Adia Nutrition, Inc. (OTC: ADIA)

ADIA Nutrition, Inc. is a regenerative medicine company focused on autologous hematopoietic stem cell transplantation and umbilical cord stem cell therapies, as well as the development and sale of premium nutritional supplements.

The company operates clinical facilities under the Adia Med brand that deliver stem cell based treatments to patients.

It also runs Adia Labs, which procures, processes and sells biologic products such as AdiaVita and AdiaLink to its clinics and to third party providers.

Through a supplement division, ADIA Nutrition, Inc. offers organic based vitamins and minerals via direct to consumer channels and an equity interest in Cement Factory, LLC.

Revenue is generated from medical services including patient treatments at Adia Med clinics and from the sale of biologic products manufactured by Adia Labs.

The supplement division contributes income through direct to consumer sales of branded products and through its stake in Cement Factory, LLC.

Additionally, the company may earn royalties or fees from licensing its proprietary stem cell preparations to other healthcare providers.

The company operates through the following segments:

• Medical Division: This segment provides autologous hematopoietic stem cell transplantation and umbilical cord stem cell treatments through clinics such as Adia Med of Winter Park, LLC and supplies biologic products via Adia Labs, LLC that are processed in FDA registered facilities and adhere to AATB standards.

• Supplement Division: This segment develops and markets premium nutritional supplements made from organic ingredients, sells them directly to consumers through electronic commerce platforms and holds an 18% equity position in Cement Factory, LLC to expand its supplement offerings.

In the regenerative tissue market, ADIA Nutrition, Inc. competes with approximately 30 to 50 other firms offering amniotic or umbilical cord based products, yet it distinguishes itself through FDA registration of its products under Section 361 of the Public Health Service Act, AATB accreditation of its laboratory and proprietary offerings such as AdiaVita guaranteeing at least 100,000,000 viable cells and 3,000,000,000,000 exosomes per unit and AdiaLink providing 3,500,000,000,000 exosomes for research.

The company’s customers include medical clinics and hospitals that administer its stem cell therapies, patients receiving autologous or umbilical cord based treatments, and individual consumers who purchase its supplement products through direct to consumer channels.